MedTrace Logo

Chemotherapy-Induced Changes to Cognition and DNA in Breast Cancer Survivors

NCT00496613 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2022-04-21

No results posted yet for this study

Summary

The purpose of this study is to learn more about how chemotherapy affects an individual's thinking abilities (cognition). Some research has shown that chemotherapy can cause changes in cognition in breast cancer survivors. However, it is not clear why this change occurs. In this study, the investigators will look to see if damage to DNA is related to these changes in cognition. Specifically, the investigators want to see 1) if women who have been treated with chemotherapy have more DNA damage than healthy women; and 2) if DNA damage is related to cognitive problems in breast cancer survivors and healthy women.

Conditions

Interventions

BEHAVIORAL

Mini-Mental State Exam and Blood draw

The neuropsychological testing will be conducted by a psychometrician who will be trained and supervised by Dr. Correa. It should take approximately 2 hours to complete.Two blood samples will be collected in green top tubes for analysis of DNA damage

BEHAVIORAL

Mini-Mental State Exam and Blood Draw

The neuropsychological testing will be conducted by a psychometrician who will be trained and supervised by Dr. Correa. It should take approximately 2 hours to complete.Two blood samples will be collected in green top tubes for analysis of DNA damage

BEHAVIORAL

Mini-Mental State Exam and Blood Draw

The neuropsychological testing will be conducted by a psychometrician who will be trained and supervised by Dr. Correa. It should take approximately 2 hours to complete.Two blood samples will be collected in green top tubes for analysis of DNA damage

Sponsors & Collaborators

Principal Investigators

  • Tim Ahles, PhD · Memorial Sloan Kettering Cancer Center

Eligibility

Min Age
50 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2022-04-18
Completion
2022-04-18

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00496613 on ClinicalTrials.gov